OLMA
NASDAQ · Biotechnology
Olema Pharmaceuticals Inc
$14.08
-0.88 (-5.88%)
Financial Highlights (FY 2025)
Revenue
273.28M
Net Income
-27,842,007
Gross Margin
29.4%
Profit Margin
-10.2%
Rev Growth
+22.4%
D/E Ratio
0.25
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 29.4% | 29.4% | 29.4% |
| Operating Margin | -11.0% | -11.2% | -12.0% |
| Profit Margin | -10.2% | -9.6% | -12.8% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 273.28M | 252.57M | 215.43M |
| Gross Profit | 80.41M | 74.31M | 63.38M |
| Operating Income | -30,097,665 | -28,310,400 | -25,859,801 |
| Net Income | -27,842,007 | -24,319,116 | -27,608,347 |
| Gross Margin | 29.4% | 29.4% | 29.4% |
| Operating Margin | -11.0% | -11.2% | -12.0% |
| Profit Margin | -10.2% | -9.6% | -12.8% |
| Rev Growth | +22.4% | +21.1% | -4.4% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 380.18M | 379.05M | 375.72M |
| Total Equity | 1.51B | 1.56B | 1.36B |
| D/E Ratio | 0.25 | 0.24 | 0.28 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -48,708,771 | -44,721,101 | -36,525,999 |
| Free Cash Flow | -19,743,741 | -20,820,819 | -13,833,937 |